Paradoxical effects of anti-TNF-α agents in inflammatory diseases (Q38170158)

30 August 2017

Paradoxical effects of anti-TNF-α agents in inflammatory diseases (English)

1 reference

30 August 2017

0 references

0 references

1

Daniel Wendling

1 reference

30 August 2017

Clément Prati

2

1 reference

30 August 2017

10 December 2013

1 reference

Expert Review of Clinical Immunology

30 August 2017

11

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

30 August 2017

10

1 reference

30 August 2017

1

1 reference

30 August 2017

159-169

1 reference

TNF alpha antagonist therapy and safety monitoring

30 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

TNF-mediated inflammatory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

TNFα: activator or inhibitor of regulatory T cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Uveitis in seronegative arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Cytokines in autoimmune uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Crohn's disease diagnosis during adalimumab treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Sarcoidosis: an underestimated and potentially severe side effect of anti-TNF-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Lichen planus under anti TNF therapy for ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Cutaneous lymphocytic vasculitis during TNFalpha antagonist therapy for polyarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Development of pyoderma gangrenosum during therapy with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

The complexity of adverse side-effects to biological agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Biologics-induced autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

Autoimmune Diseases Induced by TNF-Targeted Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.866038

10.1586/1744666X.2014.866038

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24325385